Education Resources

Through our network of global connections, we aim to make knowledge not just available, but valuable. We want to help you acquire expertise that can be directly applied to your practice. Explore the various medical education resources below:


Immunotherapy Web Featured Images 31

EHA-SWG Scientific meeting on Immunotherapy: Checkpoint inhibition in hematologi...

  Dec 03 2020 Tagged ICI

Selected from the latest EHA-SWG Scientific Meeting on Immunotherapy, we present two lectures covering the use of immune checkpoint inhibitors (ICIs) in hematology. Peter Brossart explains the mechanism of action of these drugs and Paul Bröckelmann gives an updated overview of approved and emerging indications.  

Read more
Immunotherapy Web Featured Images 37

A Primer on CAR-T Therapy: What Does It Mean for Pathologists?: A Summary Guidan...

The College of American Pathologists Personalized Health Care Committee developed a summary guidance paper to educate pathologists on CAR-T and chimeric antigen receptor-derived cellular therapy, provide a better understanding of their role in this process, explain important regulatory aspects of CAR-T therapy, and advocate for pathologist involvement in the delivery and monitoring of CAR-based treatment.

Visit website
ImmunotherapyWebsite Images Featured 39

Lymphodepletion optimization for CAR T-cell therapy

  Oct 17 2020 Tagged CAR-T, MM

At the 8th annual meeting of the Society of Hematologic Oncology (SOHO), Elizabeth Budde presented how the process of lymphodepletion can be optimized to aid persistence and efficacy of infused CAR T-cells.

Visit website
Immunotherapy Web Featured Images 21

2nd European CAR T Cell Meeting (Jan 30 - Feb 1, 2020) Report

  Oct 16 2020 Tagged CAR-T

Sections: (1) The clinical landscape for CAR-T, and current developments in Europe, (2) The global efforts to improve CAR T-cell therapy and (3) Regulatory considerations and directions for the European CAR-T landscape

Visit website
ImmunotherapyWebsite Images Featured 41

Is there an optimal time to deploy immunotherapies in multiple myeloma?

  Oct 16 2020 Tagged MM

During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to Meral Beksaç, Ankara University School of Medicine, Ankara, TR, about immunotherapy for MM: Is there an optimal time to deploy immunotherapies in multiple myeloma?

Visit website
blood4

How I treat relapsed acute lymphoblastic leukemia in the pediatric population

  Oct 15 2020 Tagged ALL, Children

Immunotherapy changed the therapeutic landscape of children with relapsed ALL. Several cases highlighting contemporary treatment decision-making are presented in this educational paper.

Visit website
Immunotherapy Web Featured Images 2

EHA CAR-T Course: Processes in CAR-T

"Processes in CAR-T" - the third CAR-T course within EHA's new immunotherapy program is now freely accessible via the EHA Campus. This course addresses processes involved in the manufacture of CAR T-cells from apheresis to treatment, as well as the role of different team members including pharmacists and nurses. It also includes considerations specific to pediatric patients.

Visit website
vjhemonic

ERIC 2020 | Developing T-cell based therapies for CLL treatment

  Oct 01 2020 Tagged CAR-T, CLL

Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, The Netherlands, discusses T-cell based therapy to treat chronic lymphocytic leukemia (CLL).

Visit website
ImmunotherapyWebsite Images Featured 36

IACH Focus on Leukemia 2020 | Antibody-based therapy to treat AML: radioimmunoco...

Farhad Ravandi, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of antibody-based therapy in acute myeloid leukemia (AML).

Visit website
ImmunotherapyWebsite Images Featured 21

Exploring the Future of CAR T-Cell Therapy in Multiple Myeloma

  Sep 17 2020 Tagged CAR-T, mAbs, MM

C. Ola Landgren, MD, PhD, chief of Myeloma Service and hematologic oncologist at Memorial Sloan Kettering Cancer Center, discusses what is next for chimeric antigen receptor (CAR) T-cell therapy in the multiple myeloma landscape.

Visit website